© 2020 NeuroRx, Inc.

*These drugs are investigational and not approved by the US FDA


Additional Indications


NeuroRx has the potential to build a pipeline of novel CNS-focused therapeutics. We believe that our leadership in the science of the N-methyl-D-asparate (NMDA) receptor, and how it may affect various disorders marked by depression, strongly positions us to pursue additional indications.


Our initial focus is on Bipolar Depression in patients with Acute Suicidal Ideation/Behavior (ASIB). Thereafter the company plans to expand into Major Depressive Disorder (MDD) in patients with ASIB. Other potential indications include chronic depression, Post-Traumatic Stress Disorder (PTSD) and Bipolar Depression marked by less acute risk levels of suicidality.

Based on our scientific leadership around the NMDA receptor,

NeuroRx has the

potential to build a

pipeline of novel,